Krensavage Asset Management LLC Has $53 Million Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR)

Krensavage Asset Management LLC increased its stake in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 49.7% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 150,205 shares of the biotechnology company's stock after buying an additional 49,873 shares during the period. United Therapeutics accounts for about 28.6% of Krensavage Asset Management LLC's holdings, making the stock its largest holding. Krensavage Asset Management LLC owned 0.34% of United Therapeutics worth $52,998,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently added to or reduced their stakes in the company. Park Avenue Securities LLC grew its position in United Therapeutics by 18.4% during the fourth quarter. Park Avenue Securities LLC now owns 2,614 shares of the biotechnology company's stock valued at $922,000 after buying an additional 407 shares during the period. Merit Financial Group LLC raised its stake in United Therapeutics by 36.6% during the fourth quarter. Merit Financial Group LLC now owns 3,463 shares of the biotechnology company's stock valued at $1,222,000 after purchasing an additional 927 shares in the last quarter. HB Wealth Management LLC bought a new position in shares of United Therapeutics in the 4th quarter valued at about $376,000. UMB Bank n.a. boosted its holdings in shares of United Therapeutics by 4.9% in the 4th quarter. UMB Bank n.a. now owns 1,101 shares of the biotechnology company's stock worth $388,000 after purchasing an additional 51 shares during the period. Finally, MassMutual Private Wealth & Trust FSB boosted its stake in United Therapeutics by 31.9% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company's stock worth $85,000 after buying an additional 58 shares during the period. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director Tommy G. Thompson sold 2,500 shares of the company's stock in a transaction on Monday, March 24th. The stock was sold at an average price of $318.80, for a total transaction of $797,000.00. Following the sale, the director now owns 8,480 shares of the company's stock, valued at approximately $2,703,424. This represents a 22.77% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Michael Benkowitz sold 10,000 shares of the company's stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $360.76, for a total value of $3,607,600.00. Following the sale, the chief operating officer now owns 2,577 shares in the company, valued at approximately $929,678.52. This trade represents a 79.51% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 55,500 shares of company stock valued at $17,054,780 in the last quarter. Insiders own 10.30% of the company's stock.

Analyst Ratings Changes

Several research analysts recently commented on the stock. Bank of America raised shares of United Therapeutics from an "underperform" rating to a "neutral" rating and set a $314.00 price target on the stock in a research note on Monday, April 21st. Wells Fargo & Company reaffirmed an "equal weight" rating and issued a $314.00 price target (down from $395.00) on shares of United Therapeutics in a report on Friday, April 25th. HC Wainwright restated a "buy" rating and set a $425.00 price target on shares of United Therapeutics in a research note on Monday, May 5th. JPMorgan Chase & Co. cut their price target on shares of United Therapeutics from $355.00 to $350.00 and set an "overweight" rating on the stock in a report on Thursday, May 1st. Finally, Morgan Stanley boosted their price objective on United Therapeutics from $346.00 to $348.00 and gave the company an "equal weight" rating in a report on Thursday, May 1st. Four equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $392.00.

United Therapeutics Stock Performance

NASDAQ UTHR opened at $305.31 on Tuesday. The business has a fifty day moving average price of $299.92 and a 200 day moving average price of $339.72. The company has a market cap of $13.77 billion, a P/E ratio of 13.41, a P/E/G ratio of 0.97 and a beta of 0.58. United Therapeutics Co. has a one year low of $264.33 and a one year high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share for the quarter, topping the consensus estimate of $6.29 by $0.34. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The business had revenue of $794.40 million for the quarter, compared to analysts' expectations of $726.82 million. During the same period in the previous year, the firm posted $6.17 EPS. The business's revenue for the quarter was up 17.2% compared to the same quarter last year. As a group, sell-side analysts predict that United Therapeutics Co. will post 24.48 EPS for the current fiscal year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.